Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of GSK1605786A in Crohn's disease
NL-OMON36684Phase 3Withdrawn
- Sponsor
- GSK
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of vercirnon in Crohn's disease, sponsored by GSK. Primary endpoint: Adverse effects. Planned start Nov 2010; status: withdrawn.
02
Drugs
vercirnon
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON36684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36684.